Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOMPENSE: Sotatercept in PAH
NCT06658522Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Amsterdam University Medical Center. Primary endpoints: Power per beat at 24 weeks and Right ventricular pulmonary artery coupling at 24 weeks. Started May 2025; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06658522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658522.